cancer vaccines, human papillomavirus 16, human papillomavirus 18, uterine cervical neoplasms"/>
J Korean Acad Fam Med Search


Journal of the Korean Academy of Family Medicine 2008;29(11):821-830.
Published online November 10, 2008.
Cervical Cancer and Human Papillomavirus Vaccines.
Sunyoung Kim, Jung Im Kwak, Yun Mi Song
Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
자궁경부암과 인유두종바이러스 백신
성균관대학교 의과대학 삼성서울병원 가정의학교실
The necessary role of genital infection by specific types of human papillomavirus (HPV) in cervical cancer development provides an opportunity to reduce the risk of cervical cancer, a second leading cancer in women, through prophylactic vaccination. Two types of vaccines targeting HPV 16 and 18 which are responsible for about 70% of all cervical cancer worldwide have been developed: a quadrivalent vaccine (Gardasil) and a bivalent vaccine (Cervarix). Gardasil also targets HPV 6 and 11 causing 90% of genital wart. Both two vaccines contain virus-like particles composed of L1 protein of viral capsid and do not exert infectivity. HPV vaccines were highly effective in preventing persistent infection by vaccine specific type HPV in young women who have not been previously exposed to them. Randomized double- blind placebo-controlled clinical trials have provided evidence that HPV vaccines have high efficacy against cervical precancerous lesion in young women irrespective of baseline HPV infection status. However, HPV vaccines neither treat existing HPV infections nor provide protection against all types of HPV related with cervical cancer. Therefore, even vaccinated females should take cervical cancer screening as recommended. Gardasil has been tested mainly in 9∼26 years old females and Cervarix in 15∼25 years old. Current recommendation for vaccination age is 9∼26 years for Gardasil and 10∼25 years for Cervarix, considering sexual debut and previous clinical trials. There are plenty of remaining issues regarding HPV vaccination such as vaccine efficacy in older women and in males, cost-effectiveness, duration of protection, cross-protection, potential replacement infection, and vaccine compatibility. (J Korean Acad Fam Med 2008;29:821-830)
Key Words: cancer vaccines, human papillomavirus 16, human papillomavirus 18, uterine cervical neoplasms


Browse all articles >

Editorial Office
Room 2003, Gwanghwamun Officia, 92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
Tel: +82-2-3210-1537    Tax: +82-2-3210-1538    E-mail:                

Copyright © 2024 by Korean Academy of Family Medicine.

Developed in M2PI

Close layer
prev next